



Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia

Yanping Yin^{1,2,3}, Paschalis Athanasiadis^{4,5}, Linda Karlsen^{1,2}, Aleksandra Urban^{1,2}, Haifeng Xu^{4,5}, Ishwarya Murali⁶, Stacey M. Fernandes⁶, Alberto J. Arribas^{7,8}, Abdul K. Hilli⁹, Kjetil Taskén^{1,2}, Francesco Bertoni^{7,10}, Anthony R. Mato¹¹, Emmanuel Normant¹², Jennifer R. Brown^{6,13}, Geir E. Tjønnfjord^{2,3}, Tero Aittokallio^{4,5,14}, and Sigrid S. Skånland^{1,2}

ABSTRACT

Purpose: PI3K inhibitors (PI3Ki) are approved for relapsed chronic lymphocytic leukemia (CLL). Although patients may show an initial response to these therapies, development of treatment intolerance or resistance remain clinical challenges. To overcome these, prediction of individual treatment responses based on actionable biomarkers is needed. Here, we characterized the activity and cellular effects of 10 PI3Ki and investigated whether functional analyses can identify treatment vulnerabilities in PI3Ki-refractory/intolerant CLL and stratify responders to PI3Ki.

Experimental Design: Peripheral blood mononuclear cell samples ($n = 51$ in total) from treatment-naïve and PI3Ki-treated patients with CLL were studied. Cells were profiled against 10 PI3Ki and the Bcl-2 antagonist venetoclax. Cell signaling and immune phenotypes were analyzed by flow cytometry. Cell viability was monitored by detection of cleaved caspase-3 and the CellTiter-Glo assay.

Results: pan-PI3Kis were most effective at inhibiting PI3K signaling and cell viability, and showed activity in CLL cells from both treatment-naïve and idelalisib-refractory/intolerant patients. CLL cells from idelalisib-refractory/intolerant patients showed overall reduced protein phosphorylation levels. The pan-PI3Ki copanlisib, but not the p110 δ inhibitor idelalisib, inhibited PI3K signaling in CD4⁺ and CD8⁺ T cells in addition to CD19⁺ B cells, but did not significantly affect T-cell numbers. Combination treatment with a PI3Ki and venetoclax resulted in synergistic induction of apoptosis. Analysis of drug sensitivities to 73 drug combinations and profiling of 31 proteins stratified responders to idelalisib and umbralisib, respectively.

Conclusions: Our findings suggest novel treatment vulnerabilities in idelalisib-refractory/intolerant CLL, and indicate that *ex vivo* functional profiling may stratify PI3Ki responders.

Introduction

Excessive and autonomous B-cell receptor (BCR) signaling is an important pathogenic mechanism in chronic lymphocytic leukemia (CLL; ref. 1), where continuous signaling leads to activation of downstream signaling molecules such as PI3K (2). Among the four classes of PI3Ks, only class I isoforms are clearly implicated in cancer (3). The catalytic subunit of class I PI3K exists as different isoforms, p110 α , β , γ , and δ . The α and β isoforms are ubiquitously

expressed, whereas γ and δ are primarily expressed in leukocytes (4). p110 δ is highly expressed in CLL cells, which makes it a promising target for CLL treatment (5). So far, two PI3K inhibitors (PI3Ki), idelalisib and duvelisib, have been approved for treatment of CLL, and several next-generation inhibitors are in development (6, 7).

Even though targeted therapies have revolutionized the management of CLL, treatment intolerance and resistance remain clinical challenges (7–9). To date, no mutations in PI3Ks are known that could explain the resistance mechanism to PI3Ki (10, 11). Rather, reports suggest that resistance to PI3Ki may be mediated by upregulation of p110 isoforms other than p110 δ (12–14). This supports the use of a pan-p110 inhibitor (here referred to as pan-PI3Ki) such as copanlisib, which is approved for indolent lymphoma. Upregulation of alternative signaling pathways may also explain the development of PI3Ki resistance in some cases. Activation of STAT3 or STAT5 by IL6 or ectopic activation of the ERBB signaling were shown to underlie resistance to various PI3Ki in lymphoma (15, 16), while activating mutations in MAPK pathway genes and upregulation of IGF1R are reported resistance mechanisms in CLL (17, 18). These resistance mechanisms provide a rationale for combination therapies, and we recently showed that MEK inhibitors are effective in idelalisib-resistant CLL (19).

Despite the initially encouraging results for PI3Ki in CLL, a more widespread use of approved PI3Ki has been limited by unexpected autoimmune toxicities (5, 7, 8, 20). Current strategies to allow for optimized use of the drug class include exploring next-generation PI3Ki and alternative dosing schedules (7, 21). Prospective clinical trials have demonstrated that patients who experience intolerance or resistance to a targeted therapy may still benefit from another drug within the same drug class (22–24). However, there is currently limited knowledge of how the overall sensitivity to PI3Ki evolves in

¹Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. ²K.G. Jebsen Centre for B-Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. ³Department of Haematology, Oslo University Hospital, Oslo, Norway. ⁴Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. ⁵Oslo Centre for Biostatistics and Epidemiology (OCBE), Faculty of Medicine, University of Oslo, Oslo, Norway. ⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ⁷Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland. ⁸SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland. ⁹Department of Medicine, Diakonhjemmet Hospital, Oslo, Norway. ¹⁰Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. ¹¹Memorial Sloan Kettering Cancer Center, New York, New York. ¹²TG Therapeutics, New York, New York. ¹³Harvard Medical School, Boston, Massachusetts. ¹⁴Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.

Corresponding Author: Sigrid S. Skånland, Oslo University Hospital, P.O. Box 4951 Nydalen, N-0424, Norway. Phone: 47-22781981; E-mail: sigrid.skånland@ous-research.no

Clin Cancer Res 2022;28:4444–55

doi: 10.1158/1078-0432.CCR-22-1221

©2022 American Association for Cancer Research

Translational Relevance

The PI3K inhibitors (PI3Ki) idelalisib and duvelisib are approved for relapsed chronic lymphocytic leukemia (CLL), but their use has been limited by severe toxicity and acquired resistance. Identification of biomarkers that predict individual treatment responses, as well as alternative treatment vulnerabilities in PI3Ki-refractory/intolerant patients, is needed to optimally tailor CLL therapy. We performed functional analyses of baseline and drug-induced cell signaling and viability in CLL cells from treatment-naïve and PI3Ki-treated patients with CLL to identify clinically actionable biomarkers. We show that CLL cells from idelalisib-refractory/intolerant patients remain sensitive to pan-PI3Ki and PI3Ki plus venetoclax combinations. A systematic analysis of drug sensitivities to 73 drug combinations stratified responders to idelalisib, while profiling of 31 proteins stratified responders to umbralisib. Our study suggests that functional testing may be used to guide precision medicine in relapsed CLL.

response to idelalisib treatment, and whether idelalisib-refractory/intolerant CLL cells remain sensitive to other PI3Ki. *Ex vivo* drug testing in patient cells has recently demonstrated clinical utility in guiding functional precision medicine for CLL and other hematological malignancies (25–27). When combined with other functional assays, such an integrated approach can lead to actionable biomarkers that predict patient treatment responses and identify unexpected treatment vulnerabilities such as novel combinations (28).

Here, we combined *ex vivo* profiling of drug sensitivity and cell signaling in response to 10 different PI3Ki (buparlisib, compound 7n, copanlisib, duvelisib, idelalisib, nemiralisib, pictilisib, pilaralisib, umbralisib, and ZSTK474) in CLL, both alone and in combination with the B-cell lymphoma-2 (Bcl-2) antagonist venetoclax. We found that pan-PI3Kis were most effective in inhibiting cell signaling and viability of CLL cells. Furthermore, pan-PI3Ki single agents and PI3Ki + venetoclax combinations showed activity both in idelalisib-resistant lymphoma cell lines and in CLL cells from idelalisib-refractory/intolerant patients. A systematic analysis of longitudinal samples from idelalisib-treated patients demonstrated significantly higher *ex vivo* combination sensitivities at baseline in patients who obtained a long-term response to idelalisib than in patients who developed resistance to idelalisib. Furthermore, profiling of 31 proteins in screening samples from patients enrolled in a phase 2 trial of umbralisib (NCT02742090; ref. 22) distinguished patients who obtained a stable disease from patients who obtained a partial response to umbralisib therapy.

Our findings indicate PI3Ki drug class activity in idelalisib-refractory/intolerant CLL and suggest that functional precision medicine based on *ex vivo* testing of drug sensitivity and cell signaling provides an exciting opportunity to predict treatment responses and to identify potential treatment options, both monotherapies and combinations. These results warrant further testing in larger cohorts and in clinical trials.

Materials and Methods

Patient material and ethical considerations

Buffy coats from age-matched, anonymized healthy blood donors were received from the Department of Immunology and Transfusion Medicine, Oslo University Hospital, Norway. Blood samples from patients with CLL were received from the Department of Hematology,

Oslo University Hospital, Norway; the Department of Medicine, Diakonhjemmet Hospital, Norway; Dana-Farber Cancer Institute (DFCI), Boston, MA; and TG Therapeutics, New York, NY (NCT02742090). All participants signed a written informed consent before sample collection. The study was approved by the Regional Committee for Medical and Health Research Ethics of South-East Norway (2016/947 and 28507). The DFCI tissue bank protocol was approved by the Dana-Farber Harvard Cancer Center Institutional Review Board. The NCT02742090 study was done in compliance with good clinical practice and local and national regulatory guidelines. An institutional review board at each site approved the protocol before any patients were enrolled. Research on blood samples was carried out in agreement with the Declaration of Helsinki.

Reagents and antibodies

Buparlisib, copanlisib, compound 7n, duvelisib, idelalisib, nemiralisib, pictilisib, pilaralisib, umbralisib, venetoclax, and ZSTK474 were obtained from Selleckchem. All compounds and combinations used in this study are listed in Supplementary Tables S1 and S2, respectively. Antibodies against AKT (pS473; D9E), cleaved caspase-3 (Asp175; D3PE), NF- κ B p65 (pS536; 93H1), p38 MAPK (pT180/Y182; 28B10), p44/42 MAPK (pT202/Y204; E10), S6-ribosomal protein (pS235/S236; D57.2.2E), and SYK (pY525/Y526; C87C1) were from Cell Signaling Technology. Antibodies against Btk (pY223)/Itk (pY180; N35–86), Btk (pY551) & p-Itk [pY511; 24a/BTK (Y551)], IgG1 Kappa (MOPC-21), MEK1 (pS298; J114–64), mTOR (pS2448; O21–404), PLC γ 2 (pY759; K86–689.37), STAT3 (pS727; 49/p-Stat3), and ZAP70/Syk (pY319/Y352; 17A/P-ZAP70) were from BD Biosciences. These antibodies were conjugated to Alexa Fluor 647. PerCP-Cy5.5 conjugated mouse anti-human CD19 antibody (HIB19) was from eBioscience. PE-Cy7 conjugated mouse anti-human CD3 antibody (UCHT1) was from BD Biosciences. Goat F(ab')₂ anti-human IgM was from Southern Biotech. BD Phosflow Fix Buffer I and Perm Buffer III were from BD Biosciences. Alexa Fluor 488, Pacific Blue, and Pacific Orange Succinimidyl Esters were from Thermo Fisher Scientific.

Kinome scan

The activities of compound 7n, copanlisib, nemiralisib, and pilaralisib were profiled at 1 μ mol/L across a panel of 468 human kinases, including atypical, mutant, lipid, and pathogen kinases, using the DiscoverX competition binding assay (<https://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinome-scan>, Eurofins Scientific, Luxembourg). The measured percentage of inhibition data are shown in Supplementary Table S3. Similar kinase activity data for buparlisib, duvelisib, idelalisib, pictilisib, umbralisib, and ZSTK474, profiled following the same kinome scan protocol, but with a panel of 442 or 468 kinases, were available from previous studies (29, 30). The activity data were visualized using the web-based tools TREEspot (Eurofins Scientific; Fig. 1) and iTOL (ref. 31; Supplementary Fig. S1).

Isolation of peripheral blood mononuclear cells

Isolation of peripheral blood mononuclear cells (PBMC) from CLL patient samples was performed as previously described (32). Isolated cells were cryopreserved in liquid nitrogen (33). See Supplementary Table S4 for patient characteristics.

Phospho flow with fluorescent cell barcoding

Experiments were performed as previously described (34, 35). For experiments shown in Figs. 2 and 4 (A–C in both figures), PBMCs from CLL153, CLL159, CLL160 and CLL216 (Supplementary Table S4)




Figure 1.


Target specificity and activity profile for 10 PI3Ki. The activity of buparlisib, compound 7n, copanlisib, duvelisib, idelalisib, nemiralisib, pictilisib, pilaralisib, umbralisib, and ZSTK474 were profiled at 1 $\mu\text{mol/L}$ over a panel of up to 468 human kinases, including atypical, mutant, lipid, and pathogen kinases (bottom dendrograms), using the DiscoverX kinase assays. The top dendrograms show (moving clockwise from the top, purple section) tyrosine kinases (TK); tyrosine kinase-like kinases (TKL); STE protein kinases (STE); casein kinase 1 family (CK1); protein kinase A, G, and C families (AGC); Ca^{2+} /calmodulin-dependent kinases (CAMK); CMGC kinase group (CMGC); and other. The size of the circles represents the percentage of target inhibition, with larger circles indicating a stronger inhibition compared with control, as defined in the scale.

were treated with the indicated compound and concentration for 30 minutes, followed by 5 minutes stimulation with anti-IgM (10 $\mu\text{g/mL}$; Southern Biotech) to activate the BCR. For experiments shown in **Fig. 2D–I**, PBMCs from CLL002D, CLL216, and CLL248 (Supplementary Table S4) were simultaneously co-cultured with irradiated (50 Gy/125 Gy/125 Gy, respectively) CD40L⁺/APRIL⁺, BAFF⁺, and APRIL⁺ 3T3 fibroblasts (ratio 1:1:1) to prevent induction of spontaneous apoptosis (36), and treated with the indicated compound and concentration for 24 hours. The treated CLL cells were then fixed, barcoded, and permeabilized as previously described (34). The samples were stained with the indicated antibodies and

analyzed with a BD LSR Fortessa cytometer (BD Biosciences) equipped with 488 nm, 561 nm, 640 nm, and 407 nm lasers. The data were analyzed in Cytobank (<https://cellmass.cytobank.org/cytobank/>) as previously described (35).

Immune phenotyping

PBMCs from each CLL donor were fixed, barcoded (34), and stained for 30 minutes with the antibody panel. The following antibodies were used: CD3-BUV395, CD4-BUV563, HLA-DR-BUV615, CD16-BUV737, CXCR5 (CD185)-BUV805, CCR7 (CD197)-BV605, CCR6 (CD196)-BV711, CD56-BV750, CD127-BV786, PD-1 (CD279)-

**Figure 2.**

Drug-induced changes in cell signaling and cell viability are PI3Ki specific. **A** and **B**, Peripheral blood mononuclear cells (PBMC) from CLL patient samples ($n = 4$) were treated with 10 PI3Ki at the indicated concentrations for 30 minutes, followed by 5 minutes anti-IgM stimulation. The cells were then fixed, permeabilized, and stained with the indicated antibodies. Signals were analyzed by flow cytometry. Results are shown for CD19⁺ B cells. Raw data were transformed to an arcsinh ratio relative to the signal in DMSO-treated control cells, which was set to zero. Curves show the mean of the four experiments. Each curve represents the response to one inhibitor. Error bars indicate standard error of the mean (SEM). **C**, Results are shown for experiments described previously in **A** and **B**. The mean inhibitory effects of the 10 PI3Ki on phosphorylation of AKT (pS473) and S6-ribosomal protein (pS235/S236) are plotted at the 1,000 nmol/L concentration. Error bars indicate SEM. **D**, CLL cells were simultaneously co-cultured with APRIL/BAFF/CD40L⁺ fibroblasts and treated with the indicated concentration of a PI3Ki or DMSO (0.1%) for 24 hours. The CLL cells were then separated from the fibroblast layer, fixed, permeabilized, and stained with the indicated antibodies. Signals were analyzed by flow cytometry. The cells were gated on CD19. The numbers indicate the fraction (%) of cells in the respective gate. Results are shown for one representative experiment. **E–G**, Experiments were performed as described previously in **D** on CLL cells from $n = 3$ patients. The blue bars indicate pan-PI3Ki. The bars show the mean fraction (%) of positive cells $\pm$ SEM. The dotted line indicates the fraction of positive cells in the DMSO control. The blue bars indicate pan-PI3Ki. **H–I**, Pearson's correlation analyses were performed on the indicated protein levels detected in **D**. Each point represents one treatment. **J**, PBMCs from $n = 6$ treatment-naïve patients with CLL were co-cultured with APRIL/BAFF/CD40L⁺ fibroblasts and DMSO (0.1%), copanlisib (100 nmol/L), or idelalisib (1 μ mol/L) for 24 hours. The PBMCs were then separated from the fibroblast layer, fixed, barcoded, permeabilized, and stained with surface markers and anti-S6-ribosomal protein (pS235/S236) antibody. Experiments were analyzed with a BD FACSsymphony A5 cytometer (BD Biosciences) and further processed in Cytobank (<https://cellmass.cytobank.org/cytobank/>). FlowSOM clustering algorithm was applied to identify cell populations, which were validated by manual gating. The UMAP dimensionality reduction algorithm was used to visualize the data. The UMAP for one representative patient sample is shown. **K**, Experiments were performed as described previously in **J**. CD19⁺/CD185^{lo} B cells were quantified as the percentage of CD3⁺ lymphocytes. **L**, Experiments were performed as described previously in **J**. Signals are shown for CD19⁺ B cells, CD4⁺ T cells, and CD8⁺ T cells. Raw data were transformed to an arcsinh ratio relative to the signal in DMSO-treated control cells, which was set to zero. Statistical testing was done with two-way ANOVA; **, $P < 0.01$; n.s., not significant.

BB700, CD14-PE, CD25-PE-CF594, CCR3 (CD183)-PE-Cy5, CD45RA-PE-Cy7, CD69-APC-R700, and CD8/CD19-APC-Cy7 (BD Biosciences). Experiments were analyzed with a BD FACSymphony A5 cytometer (BD Biosciences) and further processed in Cytobank (<https://cellmass.cytobank.org/cytobank/>). The FlowSOM clustering algorithm was applied to identify cell populations, which were validated by manual gating. The UMAP dimensionality reduction algorithm was used to visualize the data.

Cell lines

Idelalisib-resistant lines from VL51 (37) and KARPAS1718 (38) *in vitro* models were developed by prolonged exposure to the IC₉₀ concentration of idelalisib, as previously described (16, 39). The cell lines were confirmed mycoplasma negative using the MycoAlert Detection Kit (Lonza).

CellTiter-glo luminescent cell viability assay

Dose-response experiments were performed as previously described (19, 36). Compounds (Supplementary Table S1) were pre-printed in 384-well cell culture microplates using the Echo 550 liquid handler (Labcyte Inc.). Each compound was tested at five different concentrations in ten-fold increments ranging from 1 to 10,000 nmol/L (0.1–1,000 nmol/L for copanlisib). Combinations were designed using a fixed molar concentration series identical to those used for single agents. PBMCs from CLL patient samples were co-cultured with irradiated (50 Gy/125 Gy/125 Gy, respectively) CD40L⁺/APRIL⁺, BAFF⁺, and APRIL⁺ 3T3 fibroblasts (ratio 1:1:1) for 24 hours before initiation of the experiment to mimic the tumor microenvironment and to prevent spontaneous apoptosis. The CLL cells were then separated from the adherent fibroblast layer by carefully re-suspending the culturing medium and transferring it to a separate tube. Experiments on “JB” samples (Supplementary Table S4) were performed using a slightly modified protocol, in which non-irradiated fibroblasts were removed from the CLL cells by positive selection with a PE-conjugated anti-CD47 antibody and anti-PE microbeads, as previously described (19). Single-cell suspension (10,000 cells/well in 25 µL) was distributed to each well of the 384-well assay plate using the CERTUS Flex liquid dispenser (Fritz Gyger, Thun, Switzerland). Dose-response experiments on cell lines were performed on freshly thawed cells to reduce variation between experiments introduced by culturing conditions. The cells were incubated with the compounds at 37°C for 72 hours. Cell viability was measured using the CellTiter-Glo luminescent assay (Promega) according to the manufacturer’s instructions. Luminescence was recorded with an EnVision 2102 Multilabel Reader (PerkinElmer). The response readout was normalized to the negative (0.1% DMSO) and positive (100 µmol/L benzethonium chloride) controls. The measured dose-response data were processed with the KNIME software (KNIME AG).

Data analyses

Measured data from phospho flow experiments and drug sensitivity screens were processed in GraphPad Prism. Applied statistical tests are indicated in the figure legends. The normality of the data distribution was tested using the Kolmogorov–Smirnov test in GraphPad Prism 8. To quantify the compound responses, a modified drug sensitivity score (DSS) was calculated for each sample and compound separately (40). Area under the dose-response curve was calculated using an activity window from 100% to 10%, and a dose-window from the minimum concentration tested to the concentration where the viability reached 10%. DSS₃ metric was used, without the division by the logarithm of the upper asymptote of the logistic curve. Higher levels of DSS indicate

higher sensitivity to the compound. The DECREASE tool was used to predict the full dose-response matrices based on the diagonal (dose ratio 1:1) combination experiments based on normalized phospho flow data (36, 41). Combination synergy was scored using the Bliss model using the SynergyFinder web tool (42, 43).

To predict the umbralisib responders, the support vector machine (SVM) models were trained with the R-package e1071 (44). Because of the small cohort size, we treated this as a binary classification between the patients who obtained a partial response (PR) or stable disease (SD) in response to umbralisib treatment. Balanced cross-validation (CV) guaranteed that each CV fold must include at least one patient with PR and one patient with SD.

Recursive Feature Elimination (RFE) was performed using the R package caret (45, 46). Because each RFE run may select different proteins having most predictive contribution in the particular CV fold, we repeated the 3-fold CV 500 times to investigate the robustness of the protein selection and model accuracy. Finally, we ranked the proteins according to their frequency across the RFE runs (i.e., each protein can be selected a maximum of 1,500 times).

Data availability

The data generated in this study are available upon reasonable request to the corresponding author.

Results

Target specificity and activity profiles of PI3K inhibitors

The target activity of 10 PI3Ki was profiled at 1 µmol/L over a panel of up to 468 human kinases using the kinome scan assay (Fig. 1), and includes earlier reported data (29, 30). The inhibitors showed expected differences in their p110 isoform specificity and off-target activity profiles (Fig. 1; Supplementary Table S3). Among the PI3Ki, compound 7n, nemralisib, and umbralisib showed p110δ isoform-specific activity with relatively few off-target activities, whereas copanlisib and ZSTK474 showed broad activity against all four p110 isoforms and several off-target activities (Fig. 1; Supplementary Fig. S1).

Drug-induced changes in cell signaling are PI3Ki specific

To study how the different compounds inhibit PI3K signaling, CLL cells were treated with the individual PI3Ki at five concentrations (1 – 10,000 nmol/L) for 30 minutes. Copanlisib was tested at 10-fold lower concentrations (0.1 – 1,000 nmol/L) due to its higher potency (47). The cells were then stimulated with anti-IgM for 5 minutes to activate the BCR. As shown in Fig. 2A and B, each PI3Ki inhibited the phosphorylation of downstream effectors AKT (pS473) and S6-ribosomal protein (pS235/S236), but with varying potency. Overall, the pan-PI3Ki buparlisib, copanlisib, pictilisib, and ZSTK474 were most effective at inhibiting PI3K signaling (Fig. 2C). To study whether this trend could be reproduced with longer incubation times, CLL cells were incubated with each PI3Ki for 24 hours. To prevent induction of spontaneous apoptosis that would influence the read-out, the CLL cells were simultaneously co-cultured with irradiated fibroblasts expressing APRIL/BAFF/CD40L. As shown in Fig. 2D and E, 24 hours incubation with a PI3Ki inhibited phosphorylation of S6-ribosomal protein (pS235/S236), and the pan-PI3Ki were again most effective. Furthermore, 24 hours incubation with a PI3Ki induced apoptosis, as indicated by increased expression of cleaved caspase-3 (Fig. 2D and F). Similarly, expression of the anti-apoptotic protein Mcl-1 was reduced in response to PI3Ki exposure. These phenotypes were most pronounced in response to a pan-PI3Ki (Fig. 2F and G). The drug-induced changes in S6-ribosomal protein (pS236/S235) and Mcl-1

levels significantly correlated with cleavage of caspase-3 (Fig. 2H and I), indicating that alteration of cell signaling or protein expression can serve as substitute markers for induction of apoptosis.

Effects of copanlisib and idelalisib on different immune cell compartments

To study the effect of PI3K inhibition on different immune cell compartments, PBMCs from treatment-naïve patients with CLL were simultaneously cultured with fibroblasts expressing APRIL/BAFF/CD40L and treated either with DMSO (control), copanlisib (100 nmol/L), or idelalisib (1 μ mol/L) for 24 hours (Fig. 2J). The CD185^{lo} (CXCR5) B-cell population was shown to consistently expand in response to copanlisib treatment (Fig. 2K). This effect was not as pronounced upon idelalisib treatment, although two of the six patient samples showed a similar trend (Fig. 2K). CD185 is a mediator of CLL tissue homing, and it has been shown to decrease also in response to ibrutinib + rituximab treatment (48). Other analyzed immune subsets were not significantly modulated by the treatments. This is in agreement with a previous study showing specificity of idelalisib and copanlisib toward CLL B cells (47). However, we observed that copanlisib, but not idelalisib, reduced S6-ribosomal protein phosphorylation also in CD4⁺ and CD8⁺ T cells (Fig. 2L).

Pan-PI3Ki show activity in idelalisib-resistant lymphoma cells and idelalisib-refractory/intolerant CLL cells

To study the ability of the different PI3Ki to inhibit cell viability, 72 hours drug sensitivity assays were performed on the lymphoma cell lines VL51 and KARPAS1718 (Fig. 3A and B). Each PI3Ki was tested at five different concentrations (1–10,000 nmol/L). Because of its higher potency, copanlisib was tested at 10-fold lower concentrations (0.1–1,000 nmol/L). In agreement with the effects observed on cell signaling, the pan-PI3Ki buparlisib, copanlisib, pictilisib, and ZSTK474 were most effective at inhibiting cell viability in these cell lines (Fig. 3A and B, black bars).

To identify potential alternative therapies for patients who experience intolerance or develop resistance to idelalisib, we investigated whether idelalisib-resistant lymphoma cell lines remained sensitive to other PI3Ki. As expected, PI3Ki showed reduced efficacy in idelalisib-resistant cells; however, pan-PI3Ki still maintained a relatively high activity (Fig. 3A and B, blue bars). In the idelalisib-resistant VL51 cell line, the activity of the four indicated pan-PI3Ki remained between 42% (copanlisib) and 87.5% (buparlisib) relative to the activity in the parent cell line. For KARPAS1718, the corresponding range was between 27.8% (ZSTK474) and 81.4% (buparlisib). The sensitivity to idelalisib was reduced in CLL cells from idelalisib-refractory/intolerant patients as well (Fig. 3C, left). However, the sensitivity to copanlisib was maintained at similar or even higher levels than in CLL cells from treatment-naïve patients (Fig. 3C, right). This trend was also observed for the pan-PI3Ki buparlisib, pictilisib, and ZSTK474 (Supplementary Fig. S2). These findings demonstrate that pan-PI3Ki remain active in idelalisib-refractory/intolerant cells.

Idelalisib-refractory/intolerant CLL cells show reduced protein phosphorylation levels

To better understand the mechanisms underlying idelalisib-refractory/intolerant disease, we performed single-cell protein profiling of CLL cells from patients who were either treatment-naïve or refractory/intolerant to idelalisib (Fig. 3D). We found that expression or phosphorylation of several proteins was downregulated in CLL cells from

idelalisib-refractory/intolerant patients relative to treatment-naïve patients, including Bcl-2 ($P = 0.02$ with an unpaired t test), Bcl-2 (pS70; $P = 0.009$), BTK (pY551; $P = 0.004$), MEK1 (pS218)/MEK2 (pS222; $P = 0.004$), p53 (pS37; $P = 0.004$), PLC γ 2 (pY759; $P = 0.02$), STAT1 (pS727; $P = 0.01$), STAT3 (pY705; $P = 0.02$), STAT6 (pY641; $P = 0.004$), and ZAP70/SYK (pY319/Y352; $P = 0.004$). Of note, phosphorylation of proteins downstream of PI3K, including AKT (pT308), mTOR (pS2448), and TBK1 (pS172), were all significantly reduced in idelalisib-refractory/intolerant CLL cells (Fig. 3E). These findings support previous reports that have demonstrated that higher response rates to copanlisib are associated with high expression of PI3K/BCR signaling pathway genes (49, 50). We also found that the activity of p38 MAPK (pT180/Y182) was reduced in idelalisib-refractory/intolerant cells (Fig. 3E). Interestingly, we previously showed that low phosphorylation levels of p38 MAPK correlates with poor response to venetoclax (19), suggesting that cell signaling profiles may provide response markers for different classes of targeted therapies.


PI3Ki act in synergy with venetoclax to induce apoptosis in CLL cells

Targeted therapies are increasingly studied in combinations, and venetoclax has been reported to be a good combination partner for copanlisib in B-cell lymphoma (NCT03886649; ref. 51). We therefore investigated the potential benefit of combining a PI3Ki with venetoclax. CLL cells were treated with five different concentrations of each PI3Ki, venetoclax, or their combinations, for 30 minutes. The cleavage of caspase-3 was then analyzed by flow cytometry. None of the PI3Ki as a single agent induced apoptosis after this short incubation time, whereas treatment with venetoclax did (Fig. 4A). Interestingly, each PI3Ki + venetoclax combination induced higher levels of cleaved caspase-3 than the venetoclax treatment alone (Fig. 4A), suggesting a synergistic effect of the combination. Dose-response combination assays confirmed synergy among all 10 combinations (Fig. 4B and C).

Next, we tested whether PI3Ki + venetoclax combinations were effective in co-inhibiting the viability of CLL cells from idelalisib-refractory/intolerant patients over 72 hours. Overall, the sensitivities to most of these combinations were reduced in idelalisib-refractory/intolerant CLL relative to treatment-naïve CLL (Fig. 4D). However, the combinations did reduce the cell viability in a concentration-dependent manner consistently in both patient groups, as shown for idelalisib + venetoclax (Fig. 4E). Taken together, these findings show that PI3Ki act in synergy with venetoclax to induce apoptosis, and that PI3Ki + venetoclax combinations are active in both treatment-naïve and idelalisib-refractory/intolerant CLL.

Ex vivo drug sensitivity and protein profiles stratify responders to idelalisib and umbralisib therapy

To assess the predictive value of *ex vivo* drug sensitivity profiles, we analyzed drug responses to 73 combinations (Supplementary Table S2) on CLL cells from patients treated with idelalisib ("JB" samples, Supplementary Table S4). CLL cells collected at baseline from patients who obtained a long-term response to idelalisib showed significantly higher drug sensitivity scores than CLL cells from patients who obtained a short-term response (i.e., patients who developed resistance to idelalisib; Fig. 5A). Annotated drug responses are shown in Supplementary Fig. S3. After correcting for multiple comparisons, we identified significant differences in responses to three PI3Ki + venetoclax combinations (Fig. 5B). Interestingly, cells collected at the time the patients were responding to idelalisib showed lower levels of AKT (pS473) in long-term responders than in short-term responders

**Figure 3.**

Pan-PI3Ks are active in idelalisib-refractory/intolerant CLL cells. **A** and **B**, VL51 and KARPAS1718 (parent and idelalisib resistant) cell lines were treated with the indicated PI3Ki at 5 concentrations (0.1–1,000 nmol/L for copanlisib, 1–10,000 nmol/L for the others) for 72 hours. Cell viability was assessed with the CellTiter-Glo assay. The drug-sensitivity score was calculated for each treatment based on the area under the dose-response curve. High score indicates high sensitivity to the treatment. The experiments were performed twice or once (VL51 parent). The bars show average with standard deviation. **C**, PBMCs from treatment-naïve patients with CLL ($n = 7$) or idelalisib-refractory patients ($n = 9$) were co-cultured with APRIL/BAFF/CD40L⁺ fibroblasts for 24 hours. The CLL cells were then separated from the fibroblast layer and treated with the indicated compound and concentrations for 72 hours. Cell viability was assessed with the CellTiter-Glo assay. The graphs show mean relative cell viability $\pm$ standard error of the mean (SEM). **D**, Freshly thawed PBMCs from treatment-naïve patients with CLL ($n = 5$) or idelalisib-refractory patients ($n = 6$) were fixed, permeabilized, and stained with antibodies against the indicated proteins (rows). Signals were detected in CD19⁺ B cells by flow cytometry. Raw data were transformed to an arcsinh ratio relative to the signal of an isotype control (color key), which was set to zero. The heatmap was created using ClustVis (<https://biit.cs.uu.se/clustvis/>). Rows were clustered using Manhattan distance and Ward linkage. Columns were clustered using correlation distance and average linkage. **E**, Phosphorylation levels of the indicated proteins are shown for experiments described previously in **D**. The horizontal line indicates median. Statistical testing was done with the Mann-Whitney test.

(Fig. 5C), but this difference was not statistically significant, possibly due to the low number of samples in each group ($n = 3$). However, the two groups showed completely non-overlapping AKT (pS473) levels, which gives a good indication that this protein may be an accurate biomarker with high sensitivity and specificity.

To further test the predictive value of protein profiles for PI3Ki treatment outcome, we analyzed samples from 12 patients with CLL enrolled in a phase 2 clinical trial with umbralisib (NCT02742090; see

Supplementary Table S4 for the patient characteristics; ref. 22). The samples were collected at screening stage and profiled for expression or phosphorylation status of 31 proteins. We trained an SVM, a non-linear classification algorithm, using the profiles of the 31 proteins as input features with a repeated CV to avoid over-fitting. Three-fold CV was repeated 500 times to study the stability of the prediction model and its predictive features. The SVM model was able to robustly distinguish between patients who obtained a PR or SD in response




Figure 4.

PI3Ki act in synergy with venetoclax. **A**, Peripheral blood mononuclear cells (PBMC) from CLL patient samples ($n = 4$) were treated with a PI3Ki, venetoclax, or PI3Ki + venetoclax combinations, at the indicated concentrations for 30 minutes, followed by a 5-minute anti-IgM stimulation. The cells were then fixed, permeabilized, and stained with anti-cleaved caspase-3. Signals were analyzed by flow cytometry. Results are shown for CD19⁺ B cells. Raw data were transformed to an arcsinh ratio relative to the signal in DMSO-treated control cells, which was set to zero. Curves show the mean $\pm$ standard error of the mean (SEM). Statistical testing was done with a one-way ANOVA with Holm-Sidak's multiple comparisons test. *, $P < 0.05$. **B**, Normalized data from experiments described in **A** were used in DECREASE (<https://decrease.fimm.fi/>) to predict the full drug combination dose-response matrices, which were analyzed using SynergyFinder (<https://synergyfinder.fimm.fi/>) to score the synergy of the drug combinations. Bliss synergy over the full matrix is indicated. A representative plot is shown for the idelalisib + venetoclax and copanlisib + venetoclax combinations. **C**, Results are shown for analyses described previously in **B**. The most synergistic area score was calculated by SynergyFinder for the indicated combination treatments. Bars show mean ($n = 4$) $\pm$ SEM. **D**, PBMCs from treatment-naïve patients with CLL ($n = 7$) or idelalisib-refractory/intolerant patients ($n = 9$) were co-cultured with APRIL/BAFF/CD40L⁺ fibroblasts for 24 hours. The CLL cells were then separated from the fibroblast layer and treated with the indicated drug combinations for 72 hours. Cell viability was assessed with the CellTiter-Glo assay. The drug sensitivity score was calculated for each treatment based on the area under the dose-response curve. High score indicates high sensitivity to the treatment. Violin plots show min to max response with lines at quartiles and median. Statistical testing was done with an unpaired t test. *, $P < 0.05$; **, $P < 0.01$; n.s.; not significant. **E**, PBMCs from treatment-naïve patients with CLL ($n = 7$) or idelalisib-refractory/intolerant patients ($n = 9$) were co-cultured with APRIL/BAFF/CD40L⁺ fibroblasts for 24 hours. The CLL cells were then separated from the fibroblast layer and treated with idelalisib + venetoclax combination at the indicated concentrations for 72 hours. Cell viability was assessed with the CellTiter-Glo assay. The graph shows mean relative cell viability $\pm$ SEM.


to umbralisisb therapy (Fig. 5D, median prediction probabilities). However, due to the small cohort size, there was rather large variability across the CV folds (Fig. 5D, error bars). Despite the low number of patient samples, the prediction model obtained surprisingly high sensitivity, specificity, and accuracy across the 12 patients (Supplementary Fig. S4A–S4C).

Next, we used RFE to identify the proteins with most contribution to the classification accuracy. This resulted in a ranked list of the 31 proteins in terms of their importance for umbralisisb response prediction (Fig. 5E). The top three predictors were BTK (pY551), MEK1 (pS298), and AKT (pT308), which are effectors of the BCR and PI3K (Fig. 5E). The classification accuracy remained relatively high also

when the models were built with the proteins selected by RFE (Supplementary Fig. S4D–S4F).

We further investigated whether adding the *ex vivo* drug-response readouts of the patient cells to various monotherapies and combinations could improve the prediction accuracy. Because of the moderate cohort size and significant cross-correlations between the DSS and protein levels in the samples, the *ex vivo* drug sensitivities did not lead to improved accuracy compared with the protein profile model in this patient cohort and for umbralisisb treatment.

Taken together, these results demonstrate that functional profiling data may identify responders to PI3Ki, and warrant further studies in larger cohorts and clinical trials.

**Figure 5.**

Ex vivo drug sensitivity and protein profiles stratify responders to idelalisib and umbralisib therapy. **A**, Drug sensitivity screens were performed with 73 drug combinations on peripheral blood mononuclear cells (PBMC) collected from patients with CLL before the patients started treatment with idelalisib ($n = 3$ short-term responders, i.e., developed resistance to idelalisib, and $n = 3$ long-term responders). Each data point indicates the mean drug sensitivity score to one drug combination. Error bars show standard error of the mean (SEM) over the patients ($n = 3$). The diagonal line indicates equal sensitivity in long- and short-term responders. Statistical testing was done with a paired t test comparing short-term responders to long-term responders. ****, $P < 0.0001$. **B**, As in **A**, but with the indicated PI3Ki + venetoclax combinations. The dot plot shows median with range. Statistical testing was done with a two-way ANOVA with Sidak's multiple comparisons within treatment groups for the 73 drug combinations. **, $P < 0.01$. **C**, PBMCs collected from short-term and long-term responders at the time of response to idelalisib were fixed, permeabilized, and stained with anti-AKT (pS473). Signals were detected in CD19⁺ B cells by flow cytometry. Raw data were transformed to an arcsinh ratio relative to the signal of an isotype control, which was set to zero. The scatter dot plot shows median with range. Statistical testing was done with an unpaired t test. **D**, PBMCs collected at screening from patients with CLL enrolled in a phase 2 trial of umbralisib (NCT02742090) were fixed, permeabilized, and stained with antibodies against 31 proteins. The plot shows the predicted probability of partial response (PR) to umbralisib across the 12 patients with CLL. A support vector machine (SVM) model was trained using the 31 protein levels as input features with a repeated cross-validation (CV) to avoid over-fitting. Three-fold CV was repeated 500 times to study the stability of the prediction model and its features. The default probability cutoff value of 0.5 (the dotted horizontal line) distinguishes patients who obtained a PR from patients who obtained a stable disease (SD) as best response to umbralisib therapy. The boxes show the interquartile ranges, and the solid horizontal lines in each box indicate the median. Error bars show the minimum and maximum probabilities of the SVM predictions across 3-fold CVs repeated 500 times. **E**, The experiments are described previously in **D**. Recursive Feature Elimination (RFE) was performed using the R package caret. Three-fold CV was repeated 500 times to investigate the robustness of the protein selection and model accuracy. Proteins were ranked according to their frequency across the RFE runs (i.e., each protein can be selected a maximum of 1,500 times). The plot shows the frequency of the top 20 proteins selected by RFE, and the percentage indicates the proportion of CV folds. The higher the frequency the more stable and predictive is the protein for classification of patients between PR and SD classes.

Discussion

Targeted therapies have considerably improved patient outcome in CLL, but development of treatment intolerance and resistance remain clinical challenges. One strategy to prevent resistance to monotherapy is to combine therapies (9). Here, we studied the efficacy and synergy of 10 PI3Ki, both as single agents and in combination with the Bcl-2 antagonist venetoclax. Venetoclax targets the intrinsic apoptotic pathway and is therefore an attractive partner for BCR inhibitors. The combination of venetoclax with the BTK inhibitor ibrutinib has shown promising results in CLL (52–54). Numerous additional studies on CLL are currently investigating the effect of venetoclax in combination with other targeted therapies, including various PI3Ki (NCT03534323, NCT03886649, and NCT05209308). Resistance to both PI3Ki and venetoclax may be prevented or delayed with this strategy, as a suggested mechanism of resistance to venetoclax is upregulation of the PI3K/AKT/mTOR pathway (55).

Here, we showed that pan-PI3Ki were more effective than p110 δ -selective inhibitors at reducing cell viability of CLL cells, both as single agents and in combination with venetoclax. Studies of copanlisib in relapsed or refractory lymphoma have demonstrated significant efficacy and a manageable safety profile (49, 56, 57), suggesting that copanlisib is a relevant treatment option for lymphoproliferative diseases. Copanlisib plus venetoclax combination showed the highest efficacy in our *ex vivo* assays. Synergy between these compounds has been demonstrated in B- and T-cell lymphoma models (51), and the combination is currently being studied in relapsed/refractory B-cell lymphomas (NCT03886649). The results will provide further information on its safety and efficacy.

Other strategies to prevent treatment resistance include improved patient stratification or precision medicine (9). CLL is a highly heterogeneous disease, and better model systems and biomarkers to guide clinical decision making are likely to be useful. Functional assays can be valuable to this end (2, 28). *Ex vivo* drug sensitivity has successfully predicted clinical activity in hematological malignancies (25–27). For instance, the EXALT trial (NCT03096821) investigated the feasibility and clinical impact of image-based *ex vivo* drug sensitivity-guided treatment decisions in patients with aggressive refractory hematological malignancies, and showed that integration of sensitivity testing in clinical decisions led to improved treatment outcomes (25).

Here, we showed that *ex vivo* drug sensitivities and protein profiles could stratify patients based on clinical treatment responses, suggesting that such functional read-outs may serve as predictive biomarkers for treatment outcome. Our analyses showed that CLL cells from patients who are resistant to idelalisib remain sensitive to pan-PI3Ki. This finding is in agreement with studies showing that patients with CLL who fail on a targeted therapy may still benefit from a second therapy in the same drug class (22–24), and warrants further studies on how to maximize the clinical value of PI3Ki.

Taken together, our findings indicate PI3Ki drug class activity in idelalisib-refractory/intolerant CLL and suggest that functional tests may guide precision medicine and predict treatment responses.

Authors' Disclosures

L. Karlsen reports grants and personal fees from University of Oslo during the conduct of the study. K. Taskén reports grants from Research Council of Norway, Regional Health Authority for South-Eastern Norway, Norwegian Cancer Society, and Stiftelsen Kristian Gerhard during the conduct of the study. F. Bertoni reports grants from Swiss National Science Foundation during the conduct of the study, as well as other support from Helsinn, Menarini, Oncotarget Therapeutics, Bayer, Neomed, Nordic Nanovector, Spexis, NewG Lab Pharma, and AstraZeneca outside the submitted work. A.R. Mato reports grants and personal fees from Loxo, Gen-

entech, AbbVie, AstraZeneca, Genmab, Nurix, Pharmacyclics, TG Therapeutics, Octopharma, and BeiGene, as well as grants from DTRM outside the submitted work. E. Normant reports personal fees from TG Therapeutics outside the submitted work. J.R. Brown reports personal fees from AbbVie, Acerta/AstraZeneca, BeiGene, Bristol Myers Squibb/Juno/Celgene, Catapult, Eli Lilly, Genentech/Roche, Hutchmed, iOnctura, Janssen, Loxo, MEI Pharma, Morphosys AG, Nextcea, Novartis, Pfizer, Pharmacyclics, and Rigel, as well as grants from BeiGene, Gilead, Loxo/Lilly, MEI Pharma, Sun, Verastem/SecuraBio, and TG Therapeutics outside the submitted work; in addition, J.R. Brown served on the Data Safety Monitoring Committee for Invecity and Morphosys. G.E. Tjønnfjord reports research grants from Mundipharma and Alexion Pharmaceuticals, advisory board honoraria from Alexion Pharmaceuticals and Janssen-Cilag, and lecture honoraria from Novartis, Janssen-Cilag, Alexion Pharmaceuticals, and Mundipharma. S.S. Skånland reports grants from the Research Council of Norway under the frame of ERA PerMed (project number 322898), the Research Council of Norway under the frame of Digital Life Norway (project number 294916), the Norwegian Cancer Society, the Regional Health Authority for South-Eastern Norway, Stiftelsen Kristian Gerhard Jebsen (Grant 19), and the Medical Student Research Program at the University of Oslo during the conduct of the study; S.S. Skånland also reports personal fees from AbbVie and AstraZeneca, as well as non-financial support from TG Therapeutics and BeiGene outside the submitted work. No disclosures were reported by the other authors.

Authors' Contributions

Y. Yin: Investigation, visualization, writing-review and editing. **P. Athanasiadis:** Investigation, visualization, writing-review and editing. **L. Karlsen:** Investigation, writing-review and editing. **A. Urban:** Investigation, visualization, writing-review and editing. **H. Xu:** Investigation, writing-review and editing. **I. Murali:** Resources, writing-review and editing. **S.M. Fernandes:** Resources, writing-review and editing. **A.J. Arribas:** Resources, writing-review and editing. **A.K. Hilli:** Resources, writing-review and editing. **K. Taskén:** Resources, writing-review and editing. **F. Bertoni:** Resources, writing-review and editing. **A.R. Mato:** Resources, writing-review and editing. **E. Normant:** Resources, writing-review and editing. **J.R. Brown:** Resources, writing-review and editing. **G.E. Tjønnfjord:** Resources, writing-review and editing. **T. Aittokallio:** Formal analysis, supervision, writing-review and editing. **S.S. Skånland:** Conceptualization, formal analysis, supervision, investigation, visualization, writing-original draft.

Acknowledgments

The authors are thankful to all patients who contributed to this study. We are grateful to Silje Hjelbrekke, Hallvard Zapffe, Mentowa Fürst Bright, and Martine Schröder for technical assistance. We thank the High-Throughput Chemical Biology Screening Platform at Centre for Molecular Medicine Norway (NCMM), University of Oslo, and the High-Throughput Biomedicine Unit at Institute for Molecular Medicine Finland (FIMM), University of Finland, for assistance with drug sensitivity screens. We thank the Flow Cytometry Core Facilities at Oslo University Hospital for assistance and access to instrumentation. This work was supported by the Research Council of Norway under the frames of ERA PerMed (to S.S. Skånland, project number 322898) and Digital Life Norway (to K. Taskén, project number 294916), the Norwegian Cancer Society (to K. Taskén), the Regional Health Authority for South-Eastern Norway (to K. Taskén), Stiftelsen Kristian Gerhard Jebsen (to K. Taskén and G.E. Tjønnfjord, Grant 19), Lilly Constance og Karl Ingolf Larssons stiftelse (to S.S. Skånland), and the Medical Student Research Program at the University of Oslo (to L. Karlsen and S.S. Skånland). F. Bertoni was supported by Swiss National Science Foundation (SNSF 31003A_163232/1). J.R. Brown was supported by NIH R01 CA 213442. T. Aittokallio was supported by the Norwegian Cancer Society (grant 216104), Helse Sør-Øst (2020026), Radium Hospital Foundation, Finnish Cancer Foundation, the Academy of Finland (grants 310507, 313267, 326238, 340141, 345803, and 344698), and the European Union's Horizon 2020 Research and Innovation Program (ERA PerMed CLL-CLUE project).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note

Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Received April 15, 2022; revised June 17, 2022; accepted August 19, 2022; published first August 23, 2022.

References

1. von Minden MD, Übelhart R, Schneider D, Wossning T, Bach MP, Buchner M, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. *Nature* 2012;489:309–12.
2. Skånland SS, Karlsen L, Taskén K. B-cell signaling pathways—new targets for precision medicine in CLL. *Scand J Immunol* 2020;92:e12931.
3. Ortiz-Maldonado V, Garcia-Morillo M, Delgado J. The biology behind PI3K inhibition in chronic lymphocytic leukaemia. *Ther Adv Hematol* 2015;6:25–36.
4. Ferrer G, Montserrat E. Critical molecular pathways in CLL therapy. *Mol Med* 2018;24:9.
5. Brown JR. Phosphatidylinositol 3 kinase delta inhibitors: present and future. *Cancer J* 2019;25:394–400.
6. Vanhaesebroeck B, Perry MWD, Brown JR, André F, Okkenhaug K. PI3K inhibitors are finally coming of age. *Nat Rev Drug Discov* 2021;20:741–69.
7. Skånland SS, Brown JR. PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here? *Haematologica* 2022 Jul 28. [Epub ahead of print]
8. Hanlon A, Brander DM. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors. *Hematol Am Soc Hematol Educ Program* 2020;2020:346–56.
9. Skånland SS, Mato AR. Overcoming resistance to targeted therapies in chronic lymphocytic leukemia. *Blood Adv* 2021;5:334–43.
10. Ghia P, Jungström V, Tausch E, Agathangelidis A, Scheffold A, Scarfo L, et al. Whole-exome sequencing revealed no recurrent mutations within the PI3K pathway in relapsed chronic lymphocytic leukemia patients progressing under idelalisib treatment. *Blood* 2016;128:2770.
11. Scheffold A, Jebaraj BMC, Tausch E, Yahiaoui A, Dolnik A, Blaette TJ, et al. *In vivo* modeling of resistance to PI3Kδ inhibitor treatment using EμTCL1-Tg tumor transfer model. *Blood* 2016;128:190.
12. Iyengar S, Clear A, Bödör C, Maharaj L, Lee A, Calaminici M, et al. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. *Blood* 2013;121:2274–84.
13. Huw L-Y, O'Brien C, Pandita A, Mohan S, Spoerke JM, Lu S, et al. Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer. *Oncogenesis* 2013;2:e83.
14. Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. *Nature* 2015;518:240–4.
15. Kim JH, Kim WS, Park C. Interleukin-6 mediates resistance to PI3K pathway-targeted therapy in lymphoma. *BMC Cancer* 2019;19:936.
16. Arribas AJ, Napoli S, Gaudio E, Cascione L, Di Veroli A, Tarantelli C, et al. Secreted factors determine resistance to idelalisib in marginal zone lymphoma models of resistance [abstract]. *Blood* 2022;135:2569.
17. Murali I, Kasar S, Naem A, Tyekucheva S, Khalsa JK, Thrash EM, et al. Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia (CLL). *Blood* 2021;138:44–56.
18. Tausch E, Jungström V, Agathangelidis A, Zapotka M, Scarfo L, Jebaraj BMC, et al. Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than MAPK/ERK pathway mutations. *Blood* 2022;139:3340–4.
19. Melvold K, Giliberto M, Karlsen L, Ayuda-Durán P, Hanes R, Holien T, et al. Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies. *Mol Oncol* 2022;16:1153–70.
20. Richardson NC, Kasamon Y, Pazdur R, Gormley N. The saga of PI3K inhibitors in hematological malignancies: survival is the ultimate safety endpoint. *Lancet Oncol* 2022;23:563–6.
21. Roeker LE, Thompson MC, Mato AR. Searching for a home: phosphoinositide 3-kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice. *Br J Haematol* 2021;194:9–10.
22. Mato AR, Ghosh N, Schuster SJ, Lamanna N, Pagel JM, Flinn IW, et al. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy. *Blood* 2021;137:2817–26.
23. Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, et al. Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. *Haematologica* 2021;106:2364–73.
24. Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. *Lancet* 2021;397:892–901.
25. Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, et al. Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders. *Cancer Discov* 2022;12:372–87.
26. Malani D, Kumar A, Brück O, Kontro M, Yadav B, Hellesøy M, et al. Implementing a functional precision medicine tumor board for acute myeloid leukemia. *Cancer Discov* 2022;12:388–401.
27. Skånland SS, Inngjerdigen M, Bendiksen H, York J, Spetalen S, Munthe LA et al. Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case. *Haematologica* 2022;107:1994–8.
28. Letai A, Bhola P, Welm AL. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. *Cancer Cell* 2022;40:26–35.
29. Rewcastle GW, Kolekar S, Buchanan CM, Gamage SA, Giddens AC, Tsang KY, et al. Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors. *Oncotarget* 2017;8:47725–40.
30. Burris HA, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, et al. Umbralisib, a novel PI3Kdelta and casein kinase-Iepsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. *Lancet Oncol* 2018;19:486–96.
31. Letunic I, Bork P. Interactive tree of life (iTOL) v5: an online tool for phylogenetic tree display and annotation. *Nucleic Acids Res* 2021;49:W293–6.
32. Skånland SS, Cremaschi A, Bendiksen H, Hermansen JU, Thimiri Govinda Raj DB, Munthe LA, et al. An *in vitro* assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL. *Leukemia* 2020;34:478–87.
33. Hermansen JU, Tjønnfjord GE, Munthe LA, Taskén K, Skånland SS. Cryopreservation of primary B cells minimally influences their signaling responses. *Sci Rep* 2018;8:17651.
34. Skånland SS. Phospho flow cytometry with fluorescent cell barcoding for single cell signaling analysis and biomarker discovery. *J Vis Exp* 2018;140:e58386.
35. Myhrvold IK, Cremaschi A, Hermansen JU, Tjønnfjord GE, Munthe LA, Taskén K, et al. Single cell profiling of phospho-protein levels in chronic lymphocytic leukemia. *Oncotarget* 2018;9:9273–84.
36. Athanasiadis P, Ianevski A, Skånland SS, Aittokallio T. Computational pipeline for rational drug combination screening in patient-derived cells. *Methods Mol Biol* 2022;2449:327–48.
37. Inokuchi K, Abo J, Takahashi H, Miyake K, Inokuchi S, Dan K, et al. Establishment and characterization of a villous lymphoma cell line from splenic B-cell lymphoma. *Leuk Res* 1995;19:817–22.
38. Martinez-Climent JA, Sanchez-Izquierdo D, Sarsotti E, Blesa D, Benet I, Climent J, et al. Genomic abnormalities acquired in the blastic transformation of splenic marginal zone B-cell lymphoma. *Leuk Lymphoma* 2003;44:459–64.
39. Arribas AJ, Napoli S, Cascione L, Sartori G, Barnabei L, Gaudio E, et al. Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis. *Haematologica* 2022 Apr 28. [Epub ahead of print]
40. Yadav B, Pemovska T, Szewajda A, Kuleskiy E, Kontro M, Karjalainen R, et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. *Sci Rep* 2014;4:5193.
41. Ianevski A, Giri AK, Gautam P, Kononov A, Potdar S, Saarela J, et al. Prediction of drug combination effects with a minimal set of experiments. *Nat Mach Intell* 2019;1:568–77.
42. Bliss C. The toxicity of poisons applied jointly. *Ann Appl Biol* 1939;26:585–615.
43. Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose–response matrix data. *Bioinformatics* 2017;33:2413–5.
44. Meyer D, Dimitriadou E, Hornik K, Weingessel A, Leisch F. e1071: Misc Functions of the Department of Statistics, Probability Theory Group (Formerly: E1071), TU Wien. R package version 1.7-11. 2022. Available from: <https://CRAN.R-project.org/package=e1071>.
45. Guyon I, Weston J, Barnhill S, Vapnik V. Gene selection for cancer classification using support vector machines. *Machine Learning* 2002;46:389–422.
46. Kuhn M. Building predictive models in R using the caret package. *J Stat Softw* 2008;28:1–26.
47. Göckeritz E, Kerwen S, Baumann M, Wigger M, Vondevy V, Neumann L, et al. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. *Int J Cancer* 2015;137:2234–42.
48. Peragine N, De Propriis MS, Intoppa S, Milani ML, Mariglia P, Mauro FR, et al. Modulated expression of adhesion, migration and activation molecules may

- predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab. *Haematologica* 2020;106:1500–3.
49. Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. *J Clin Oncol* 2017;35:3898–905.
 50. Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. *Ann Oncol* 2017;28:2169–78.
 51. Tarantelli C, Lange M, Gaudio E, Cascione L, Spriano F, Kwee I, et al. Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. *Blood Adv* 2020;4:819–29.
 52. Hillmen P, Rawstron AC, Brock K, Muñoz-Vicente S, Yates FJ, Bishop R, et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study. *J Clin Oncol* 2019;37:2722–9.
 53. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and venetoclax for first-line treatment of CLL. *N Engl J Med* 2019;380:2095–103.
 54. Kater AP, Levin M-D, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, et al. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial. *Lancet Oncol* 2022;23:818–28.
 55. Choudhary GS, Al-harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. *Cell Death Dis* 2015;6:e1593.
 56. Lenz G, Hawkes E, Verhoef G, Haioun C, Thye Lim S, Seog Heo D, et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. *Leukemia* 2020;34:2184–97.
 57. Panayiotidis P, Follows GA, Mollica L, Nagler A, Özcan M, Santoro A, et al. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. *Blood Adv* 2021;5:823–8.